Literature DB >> 30148658

Time Is Money: Optimizing the Scheduling of Nivolumab.

Mark J Ratain1, Daniel A Goldstein1.   

Abstract

Year:  2018        PMID： 30148658     DOI： 10.1200/JCO.18.00045

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

Review 1.  Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.

Authors:  Etienne Chatelut; Félicien Le Louedec; Gérard Milano
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

2.  Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).

Authors:  Manish R Sharma; Shailly Mehrotra; Elizabeth Gray; Kehua Wu; William T Barry; Clifford Hudis; Eric P Winer; Alan P Lyss; Deborah L Toppmeyer; Alvaro Moreno-Aspitia; Thomas E Lad; Mario Velasco; Beth Overmoyer; Hope S Rugo; Mark J Ratain; Jogarao V Gobburu
Journal:  J Clin Pharmacol       Date:  2019-12-04       Impact factor: 3.126

Review 3.  Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development.

Authors:  Pottayil G Sasikumar; Murali Ramachandra
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 4.  Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Authors:  Cody J Peer; Daniel A Goldstein; Jennifer C Goodell; Ryan Nguyen; William D Figg; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2020-06-11       Impact factor: 3.716

Review 5.  Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Authors:  Kartik Sehgal; Daniel B Costa; Deepa Rangachari
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

6.  'The same old story': thoughts on authorized doses of anticancer drugs.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Ther Adv Med Oncol       Date:  2020-02-22       Impact factor: 8.168

Review 7.  Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.

Authors:  Etienne Chatelut; Jeroen J M A Hendrikx; Jennifer Martin; Joseph Ciccolini; Dirk Jan A R Moes
Journal:  Pharmacol Res Perspect       Date:  2021-04

Review 8.  Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Authors:  Christophe Maritaz; Sophie Broutin; Nathalie Chaput; Aurélien Marabelle; Angelo Paci
Journal:  J Hematol Oncol       Date:  2022-01-15       Impact factor: 17.388

9.  Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Authors:  Kartik Sehgal; Anushi Bulumulle; Heather Brody; Ritu R Gill; Shravanti Macherla; Aleksandra Qilleri; Danielle C McDonald; Cynthia R Cherry; Meghan Shea; Mark S Huberman; Paul A VanderLaan; Glen J Weiss; Paul R Walker; Daniel B Costa; Deepa Rangachari
Journal:  Clin Lung Cancer       Date:  2020-06-05       Impact factor: 4.785

Review 10.  Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.

Authors:  Félicien Le Louedec; Fanny Leenhardt; Clémence Marin; Étienne Chatelut; Alexandre Evrard; Joseph Ciccolini
Journal:  Vaccines (Basel)       Date:  2020-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.